Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Research to lead to brain tumor therapies

Research to lead to brain tumor therapies

March 24, 2008

Unique human in vitro model research currently underway at the Peninsula Medical School in the southwest of England is set to identify and develop therapies for the treatment of multiple tumors in the brain

Unique human in vitro model (cell culture) research currently underway at the Peninsula Medical School in the South West of England is set to identify and develop therapies for the treatment of multiple tumours in the brain.




The tumours are caused by mutations affecting a protein called merlin, which in turn cause cancers in a range of cell types including Schwann cells in the brain. Schwann cells produce the sheaths that surround and insulate neurons.

Although the tumours are benign, they are frequent, can be inherited and come in numbers. The sheer number of them can overwhelm a patient, often leading to deafness and eventually death. Patients can suffer from 20 to 30 tumours at any one time, and the condition typically affects older children and adults.

No therapy, other than invasive surgery aiming at a single tumour and which may not eradicate the full extent of the tumours, exists.

The condition of multiple tumours is known as neurofibromatosis type two (NF2) and affects one in every 2,500 people worldwide. It can affect any family, regardless of past history, through gene mutation and currently there is no cure.

Research at the Peninsula Medical School is led by Professor Oliver Hanemann. By working with human cells in vitro, Professor Hanemann and his team are able to find new therapeutic targets for NF2. They have secured initial success by re-profiling an existing drug, sorafenib, and because they are using the human in cell culture model and re-profile new cancer drugs they do not need to carry out huge toxicity studies - which means they now can go straight to clinical trials and introduce therapies to patients sooner rather than later using sorafenib or similar drugs.

Said Professor Hanemann: "Ours is a unique model and a unique approach to the issue. We are on the verge of working with inpatient clinics to trial our latest breakthrough, and we are investigating other therapeutic targets using other drugs."

He added: "Using human in vitro cell culture, which is the unique aspect of our work, allows us to move seamlessly and relatively quickly from lab-based biochemistry to drug therapies, clinical trials and hopefully successful outcomes."

Maria Toman, chair, the Neurofibromatosis Association, commented: "The Neurofibromatosis Association (www.nfauk.org), as the only charity working in the UK with patients and families affected by neurofibromatosis, welcomes this breakthrough heralding the possibility of new, non invasive treatment for NF2 with the potential to transform management of this debilitating and long term condition, and will be watching progress of the trials with close interest. Our members have benefited hugely from Professor Hanemann's clinical work since his arrival at the Peninsula Medical School and by his establishment of the first specialist neurofibromatosis clinic in the South West of England. We hope that similar approaches in neurofibromatosis type one, one of the commonest genetic diseases, will bring treatment trials in the near future."

Dr. Kim Hunter-Schaedle, chief scientific officer of the Children's Tumor Foundation said: "Dr. Hanemann's work is very exciting. There is currently no effective treatment for neurofibromatosis. As a physician and researcher he should be able to take positive results quickly from the bench to the patient, getting promising neurofibromatosis drug therapies as quickly as possible into clinical trials. " The Children's Tumour Foundation has provided seed funding to Professor Hanemann and to an international consortium of research establishments of which the Peninsula Medical School is one. It will fund over $3 million for neurofibromatosis research programmes in 2008. More information is available by logging on at http://www.ctf.org.

More information is available by logging on at http://www.pms.ac.uk.

CASE STUDY

Tom Wakenshaw, 21, from Gunnislake in Cornwall, first became aware that there was a problem when he started to suffer from very bad headaches at age 15.

He was a pupil at Tavistock College at the time and in the middle of his GCSEs. He was referred for an MRI which identified a tumour on his brain, and was immediately rushed to Bristol for surgery to remove it.

Said Tom: "I had the operation, and then they told me afterwards that I had neurofibromatosis. When you're young you just take these things on board, which is what I did at the time. But it has had a huge effect on my life since."

Tom lives with his mother Val, and is currently being helped by the local Job Centre to try to find a job that can accommodate the effects of the neurofibromatosis. The condition causes him to get very tired and affects his balance. The operations he has had over the past years to remove more tumours have resulted in numb fingertips and feet.

He said: "I had a job as a window cleaner once, but a had an accident where a nail slipped between my toes. The worrying thing was that, even though it did not go into me, I couldn't feel it passing by my toes."

Tom is currently working with his local Job Centre which his finding him placements - his next is a six week spell working in the kitchen at the Bedford Hotel in Tavistock.

Tom is the youngest of four children, and some of his family live close by. Said Tom: "My Mum, Dad and brother live locally and see what it's like on a day-to-day basis. It's good to have them close by."

Tom attends the clinics run by Professor Oliver Hanemann at Derriford Hospital in Plymouth. "They're really useful, and a good opportunity to talk about how I'm doing," said Tom. "Professor Hanemann gives us good ideas and suggestions to help cope with the condition, and just talking about it is a great help."

The Peninsula College of Medicine and Dentistry



Related Neurofibromatosis Current Events and Neurofibromatosis News Articles Neurofibromatosis Current Events and Neurofibromatosis News RSS Neurofibromatosis Current Events and Neurofibromatosis News RSS
Loss of tumor supressor gene essential to transforming benign nerve tumors into cancers
Researchers at UCLA's Jonsson Comprehensive Cancer Center showed for the first time that the loss or decreased expression of the tumor suppressor gene PTEN plays a central role in the malignant transformation of benign nerve tumors called neurofibromas into a malignant and extremely deadly form of sarcoma.

New research strategy for understanding drug resistance in leukemia
UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.

Anti-angiogenesis treatment improves hearing in some NF2 patients
Treatment with the angiogenesis inhibitor bevacizumab improved hearing and alleviated other symptoms in patients with neurofibromatosis type 2 (NF2).

Chromosomal problems affect nearly all human embryos
For the first time, scientists have shown that chromosomal abnormalities are present in more than 90% of IVF embryos, even those produced by young, fertile couples.

Rice University study finds possible clues to epilepsy, autism
Rice University researchers have found a potential clue to the roots of epilepsy, autism, schizophrenia and other neurological disorders.

Mapping a clan of mobile selfish genes
Much of human DNA is the genetic equivalent of e-mail spam: short repeated sequences that have no obvious function other than making more of themselves.

Pediatric study finds alternatives for radiation of low-grade brain tumors
A multi-institutional study led by researchers at The University of Texas M. D. Anderson Cancer Center has found that using chemotherapy alone and delaying or avoiding cranial radiation altogether can be effective in treating pediatric patients with unresectable or progressive low-grade glioma.

Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
An experimental anti-cancer drug can prevent -- and even reverse -- potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, National Institutes of Health (NIH) researchers reported today.

Gene's newly explained effect on height may change tumor disorder treatment
A mutation that causes a childhood tumor syndrome also impairs growth hormone secretion, researchers at Washington University School of Medicine in St. Louis have found.

Protein key to neuro-regeneration
Researchers at the Peninsula Medical School in the South West of England, University College London, the San Raffaele Scientific Institute in Milan and Cancer Research UK, have for the first time identified a protein that is key to the regeneration of damage in the peripheral nervous system and which could with further research lead to understanding diseases of our peripheral nervous systems and provide clues to methods of repairing damage in the central nervous system.
More Neurofibromatosis Current Events and Neurofibromatosis News Articles
Neurofibromatosis: A Handbook for Patients, Families and Health Care Professionals

Neurofibromatosis: A Handbook for Patients, Families and Health Care Professionals
by Bruce Korf (Editor), Allen Rubenstein (Editor)

Here is the state-of-the-art on recognizing, managing and living with neurofibromatosis (NF) for patients, families, and health care professionals. From new genetic and diagnostic advances, to associated cardiovascular and endocrine abnormalities, to the significant psychosocial impact of NF, the book is packed with clear, practical guidance for understanding and living with this disability.

Special features -

- A complete diagnostic guide to help you recognize NF-related symptoms--with a timeline for when they might appear

- New treatment options for NF, including pain control

- Coverage of the newly discovered form of NF, schwannomatosis

- Personal perspectives from NF patients and their families

- Glossary that defines medical terminology ...

Neurofibromatosis Medical Guide

Neurofibromatosis Medical Guide
by Qontro Medical Guides (Author)

The Neurofibromatosis Medical Guide is a publication which has been designed to better help readers understand Neurofibromatosis. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Neurofibromatosis. The Neurofibromatosis Medical Guide is highly recommended for those interested in understanding and learning more about Neurofibromatosis.

Neurofibromatosis: Phenotype, Natural History, and Pathogenesis (Johns Hopkins Series in Contemporary Medicine and Public Health)

Neurofibromatosis: Phenotype, Natural History, and Pathogenesis (Johns Hopkins Series in Contemporary Medicine and Public Health)
by Dr. J. M. Friedman MD PhD (Editor), Dr. David H. Gutmann MD-PhD (Editor), Dr. Mia MacCollin MD (Editor), Dr. Vincent M. Riccardi MD (Editor)

Univ. of British Columbia, Canada. Combines the Neurofibromatosis Institute Database with the International NF Database and the National NF Foundation. This edition sees an increased emphasis on NF2, in clinical and molecular terms. Previous edition: c1992. Includes evaluation and management, cognitive function and academic performance, and more.

  Neurofibromatosis: a young woman's journey--case study.(Case study): An article from: Journal of Neuroscience Nursing
by Susan Milliken (Author)

This digital document is an article from Journal of Neuroscience Nursing, published by Thomson Gale on December 1, 2007. The length of the article is 1833 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Neurofibromatosis: a young woman's journey--case study.(Case study)
Author: Susan Milliken
Publication: Journal of Neuroscience Nursing (Magazine/Journal)
Date: December 1, 2007
Publisher: Thomson Gale
Volume: 39 Issue: 6 Page: 332(4)

Article Type: Case study

Distributed by Thomson...

Neurofibromatosis Type I in Childhood

Neurofibromatosis Type I in Childhood
by Kathryn North (Author)

A great deal is now known about neurofibromatosis type 1, particularly as a result of the identification of its causative gene by positional cloning. However, effective treatments for its resulting cosmetic disfigurement, impaired cognitive performance and even life-threatening malignancy remain elusive. As Dr. Korf remarks in his Foreword: "this book's cogent and thorough description of neurofibromatosis in children will take its place alongside other major clinical studies of the disorder. [Dr. North] has tackled some of the more challenging issues, such as the basis for learning disabilities and the optimal means for early detection of optic gliomas. Her work provides a guide to the clinician and stands as a provocative challenge to the neurofibromatosis research community to further...

Living with Genetic Disorder: The Impact of Neurofibromatosis 1

Living with Genetic Disorder: The Impact of Neurofibromatosis 1
by Joan Ablon (Author)

A chronicle of the life experiences of adults with neurofibromatosis 1, a neurological genetic condition for many years misdiagnosed as "The Elephant Man's Disease." Affected persons deal with an unpredictable and potentially stigmatizing disorder, the symptoms of which range from physical disfigurement to severe learning disorders. Ablon offers suggestions for families, support systems, and health care providers to enhance coping skills and self image of the affected persons.

ABC News Nightline Listen Lesson in Patients

ABC News Nightline Listen Lesson in Patients

ABC News looks at how Harvard Medical School is creatively teaching its students one of the most important skills for a physician - how to listen to their patients. ABC News also meets Porter Colley, a 73- year old woman who suffers from neurofibromatosis.

Airdate: 9/1/2000

This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply.

Neurofibromatosis Awareness Ribbon Mouse Pad

Neurofibromatosis Awareness Ribbon Mouse Pad
by MyHeritageWear.com

The Neurofibromatosis Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Neurofibromatosis Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Neurofibromatosis Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness!

  Neurofibromatosis: Trusting God in the midst of NF
by Renee B Wilson (Author)



Neurofibromatosis - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Neurofibromatosis - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
by ICON Health Publications (Author)

In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing.This book was created for medical professionals, students, and members of the general public who want to conduct medical research using the most advanced tools available and spending the least amount of time doing so.

© 2009 BrightSurf.com